Continue reading this on our app for a better experience

Open in App
Floating Button
Home Capital Results

Livingstone Health reports 56% growth in earnings of $2.1 mil for 1HFY22

Felicia Tan
Felicia Tan • 2 min read
Livingstone Health reports 56% growth in earnings of $2.1 mil for 1HFY22
Looking ahead, Livingstone Health Holdings expects its performance in the FY2022 to improve compared to that of FY2021.
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Livingstone Health Holdings has reported earnings of $2.05 million for the 1HFY2022 ended September, 56% higher than earnings of $1.3 million in the same period before.

Earnings per share (EPS) stood at 0.65 cent on a diluted basis, up from 0.42 cent in the 1HFY2021.

This is the first set of half-year results reported since the company listed on SGX’s Catalist board following a reverse takeover (RTO) completed on Feb 5.

Revenue for the half-year period surged 97% y-o-y to $16.0 million due to improved contributions from the company’s existing business segments.

The growth across all segments was attributable to the addition of doctors including specialists in the anaesthesiology and pain management segment, new medical practices and allied healthcare services. The company, in addition to establishing a family practice in Novena under its Phoenix Medical Group, now has 16 medical doctors practising at 14 medical clinics.

Maiden contributions from new initiatives, as well as the sale and the administration of Sinovac vaccines also helped lift the company’s half-year revenue.

See also: Trump wins Republican nomination, setting up rematch with Biden

Other income increased by 1% y-o-y to $602,000, while share of loss from joint ventures fell 21% y-o-y to $69,000.

For the 1HFY2022, net profit after tax increased by 62% y-o-y to $2.14 million.

Looking ahead, Livingstone Health Holdings expects its performance in the FY2022 to improve compared to that of FY2021, due to the procurement of the vaccine, distribution and administration via Phoenix Medical Group.

See also: OCBC posts record net profit of $7.02 billion for FY2023, up 27% y-o-y; plans final dividend of 42 cents

The company’s performance in the FY2022 will also include growth strategies and the absence of the financial effects of the RTO and RTO-related professional costs.

“Despite the Covid-19 pandemic, we have achieved several significant milestones such as the opening of Ardennes Healthcare, Atlas Podiatry, PMG Novena and appointment by MOH to lead procurement of Sinovac vaccines in Singapore,” says Dr Wilson Tay, CEO of Livingstone Health.

“This achievement highlights our execution ability on key growth strategies. We will continue to focus on implementing strategies to strengthen our ecosystem, which will translate into added value for our shareholders,” he adds.

Shares in Livingstone closed 0.1 cent lower or 0.65% down at 15.3 cents on Nov 1.

Photo: Albert Chua/The Edge Singapore

Highlights

Re test Testing QA Spotlight
1000th issue

Re test Testing QA Spotlight

Get the latest news updates in your mailbox
Never miss out on important financial news and get daily updates today
×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.